AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

SAREUM HOLDINGS PLC

AGM Information Dec 22, 2016

7898_dva_2016-12-22_857a6e19-1be0-4389-93fa-e5ebe35f1a2f.html

AGM Information

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 6018S

Sareum Holdings PLC

22 December 2016

SAREUM HOLDINGS PLC

("Sareum" or "the Company")

Result of General Meeting

Sareum (AIM: SAR), the specialist cancer drug discovery and development business, announces that at the General Meeting held earlier today, the resolution was duly passed.

For further information:

Sareum Holdings plc
Tim Mitchell 01223 497 700
WH Ireland Limited (Nominated Adviser and Co-Broker)
Chris Fielding / Nick Prowting 020 7220 1666
Hybridan LLP (Co-Broker)
Claire Noyce / William Lynne 020 3764 2341/2342
The Communications Portfolio (Media enquiries)
Ariane Comstive

[email protected]
07785 922 354

Notes for editors:

Sareum is a drug discovery and development company delivering targeted small molecule therapeutics, focusing on cancer and autoimmune disease, for licensing to pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.

Sareum operates an outsourced research model, working with international collaborators and a world-wide network of research providers. Its most advanced programme (Chk1) commenced clinical trials in May 2016 and was licensed to NASDAQ-listed ProNAi Therapeutics in September 2016.

SKIL(R) (Sareum Kinase Inhibitor Library) is Sareum's drug discovery technology platform that has so far produced the Company's Aurora+FLT3 and TYK2 kinase cancer and autoimmune disease research programmes, which are in the IND-enabling preclinical and lead optimisation stages respectively. SKIL(R) can also generate drug research programmes against other kinase targets.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the symbol SAR. For further information, please visit www.sareum.co.uk

This information is provided by RNS

The company news service from the London Stock Exchange

END

ROMLIFSAFRLFFIR

Talk to a Data Expert

Have a question? We'll get back to you promptly.